QuantaMatrix

QuantaMatrix ROE

The Return on Equity (ROE) of QuantaMatrix (317690.KQ) as of Oct 26, 2026 is -48.64 %. In the previous year, Return on Equity (ROE) was -308.83 % — a change of -84.25% (higher).

ROE

-48.64 %

YoY

-84.25%

Last updated:

In 2025, QuantaMatrix's return on equity (ROE) was -48.64 %, a -84.25% increase from the -308.83 % ROE in the previous year.

The QuantaMatrix ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
38.56 KRW
Jan 1, 2019
-217.94 KRW
Jan 1, 2020
-25.54 KRW
Jan 1, 2021
-31.02 KRW
Jan 1, 2022
-48.24 KRW
Jan 1, 2023
-118.96 KRW
Jan 1, 2024
-308.83 KRW
Jan 1, 2025
-48.64 KRW
The QuantaMatrix ROE history
YEARROEYoY
-48.64 %-84.25%
-308.83 %+159.60%
-118.96 %+146.62%
-48.24 %+55.48%
-31.02 %+21.48%
-25.54 %-88.28%
-217.94 %-665.19%
38.56 %-17.22%
46.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

QuantaMatrix Stock analysis

What does QuantaMatrix do? QuantaMatrix Inc. generates revenue through the sale of its multi-diagnostic unique test platform, micro disc, antimicrobial susceptibility testing sepsis diagnostic equipment, molecular immunity diagnosis automation platform, rapid antituberculosis susceptibility testing equipment, and rapid antituberculosis susceptibility testing kits. The company also sells covid kits and conducts research and development for microbial diagnostic products. Its primary customers include healthcare facilities and laboratories requiring advanced diagnostic solutions for microbiological and molecular testing. The firm targets segments focused on infectious disease diagnostics, antimicrobial resistance testing, and rapid tuberculosis detection. The company's product portfolio emphasizes innovative diagnostic tools, with a strong focus on sepsis diagnostics and tuberculosis testing. By offering both equipment and kits, QuantaMatrix addresses diverse needs within the healthcare sector. The firm's research and development activities support continuous product enhancement and expansion into new diagnostic areas. QuantaMatrix Inc. serves the global market for diagnostic equipment, with particular emphasis on regions where infectious disease management is critical. Its products are designed to meet the demands of healthcare providers seeking efficient, accurate, and rapid diagnostic solutions. The company's strategy centers on leveraging its technological expertise to capture market share in specialized diagnostic segments. QuantaMatrix is one of the most popular companies on Eulerpool.

ROE Details

Decoding QuantaMatrix's Return on Equity (ROE)

QuantaMatrix's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing QuantaMatrix's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

QuantaMatrix's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in QuantaMatrix’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about QuantaMatrix stock

Return on Equity (ROE) of QuantaMatrix is -48.64 % in 2025.

Return on Equity (ROE) of QuantaMatrix changed from -308.83 % to -48.64 %, representing a -84.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) QuantaMatrix since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s QuantaMatrix with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — QuantaMatrix

All Key Metrics — QuantaMatrix